Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$11.08
-0.55-4.73%
At close: -
$11.08
0.000.00%
After Hours: 4:34 PM EDT
Comments
Loading...
Oruka Therapeutics Analyst Ratings and Price Targets | NASDAQ:ORKA | Benzinga
Oruka Therapeutics Inc has a consensus price target of $40.33 based on the ratings of 10 analysts. The high is $49 issued by Stifel on October 11, 2024. The low is $20 issued by Wolfe Research on February 4, 2025. The 3 most-recent analyst ratings were released by Wedbush, HC Wainwright & Co., and Wolfe Research on May 15, 2025, February 7, 2025, and February 4, 2025, respectively. With an average price target of $35 between Wedbush, HC Wainwright & Co., and Wolfe Research, there's an implied 215.88% upside for Oruka Therapeutics Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Wedbush
HC Wainwright & Co.
Wolfe Research
Stifel
Leerink Partners
1calculated from analyst ratings
Analyst Ratings for Oruka Therapeutics
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 05/15/2025 | Buy Now | 261.01% | Wedbush | Martin Fan 51% | $40 → $40 | Reiterates | Outperform → Outperform | Get Alert |
| 02/07/2025 | Buy Now | 306.14% | HC Wainwright & Co. | Mitchell Kapoor46% | $45 → $45 | Reiterates | Buy → Buy | Get Alert |
| 02/04/2025 | Buy Now | 80.51% | Wolfe Research | Andy Chen48% | → $20 | Initiates | → Outperform | Get Alert |
| 12/20/2024 | Buy Now | 306.14% | HC Wainwright & Co. | Mitchell Kapoor46% | $45 → $45 | Reiterates | Buy → Buy | Get Alert |
| 11/25/2024 | Buy Now | 306.14% | HC Wainwright & Co. | Mitchell Kapoor46% | $45 → $45 | Reiterates | Buy → Buy | Get Alert |
| 10/31/2024 | Buy Now | 306.14% | HC Wainwright & Co. | Mitchell Kapoor46% | $45 → $45 | Reiterates | Buy → Buy | Get Alert |
| 10/11/2024 | Buy Now | 342.24% | Stifel | Alex Thompson43% | → $49 | Initiates | → Buy | Get Alert |
| 10/07/2024 | Buy Now | 306.14% | HC Wainwright & Co. | Mitchell Kapoor46% | → $45 | Initiates | → Buy | Get Alert |
| 09/17/2024 | Buy Now | 297.11% | Leerink Partners | David Risinger71% | → $44 | Initiates | → Outperform | Get Alert |
| 09/17/2024 | Buy Now | 297.11% | Leerink Swann | David Risinger71% | → $44 | Initiates | → Outperform | Get Alert |
| 09/16/2024 | Buy Now | 270.04% | LifeSci Capital | — | → $41 | Initiates | → Outperform | Get Alert |
| 09/16/2024 | Buy Now | — | TD Cowen | Tyler Van Buren44% | — | Initiates | → Buy | Get Alert |
| 09/13/2024 | Buy Now | 261.01% | Jefferies | Michael Yee56% | → $40 | Initiates | → Buy | Get Alert |
| 09/04/2024 | Buy Now | 261.01% | Wedbush | David Nierengarten61% | → $40 | Initiates | → Outperform | Get Alert |
FAQ
What is the target price for Oruka Therapeutics (ORKA) stock?
The latest price target for Oruka Therapeutics (NASDAQ:ORKA) was reported by Wedbush on May 15, 2025. The analyst firm set a price target for $40.00 expecting ORKA to rise to within 12 months (a possible 261.01% upside). 14 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Oruka Therapeutics (ORKA)?
The latest analyst rating for Oruka Therapeutics (NASDAQ:ORKA) was provided by Wedbush, and Oruka Therapeutics reiterated their outperform rating.
When was the last upgrade for Oruka Therapeutics (ORKA)?
There is no last upgrade for Oruka Therapeutics
When was the last downgrade for Oruka Therapeutics (ORKA)?
There is no last downgrade for Oruka Therapeutics.
When is the next analyst rating going to be posted or updated for Oruka Therapeutics (ORKA)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Oruka Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Oruka Therapeutics was filed on May 15, 2025 so you should expect the next rating to be made available sometime around May 15, 2026.
Is the Analyst Rating Oruka Therapeutics (ORKA) correct?
While ratings are subjective and will change, the latest Oruka Therapeutics (ORKA) rating was a reiterated with a price target of $40.00 to $40.00. The current price Oruka Therapeutics (ORKA) is trading at is $11.08, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
